



Dedicated to you

## Financial Statements

**Ceylon Hospitals PLC**

*For the 4th Quarter ended 31st March 2023*

## Consolidated Statement of Profit or Loss and Other Comprehensive Income

	Group				Accumulated Period of 12 Months			
	Group		Company		Group		Company	
	03 Months Ended 31/03/2023	03 Months Ended 31/03/2022	03 Months Ended 31/03/2023	03 Months Ended 31/03/2022	12 Months Ended 31/03/2023	12 Months Ended 31/03/2022	12 Months Ended 31/03/2023	12 Months Ended 31/03/2022
	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Unaudited Rs. '000	Audited Rs. '000	Unaudited Rs. '000	Audited Rs. '000
<b>Revenue</b>	<b>2,150,801</b>	2,028,053	<b>1,173,372</b>	1,173,273	<b>7,905,210</b>	7,840,801	<b>4,369,878</b>	5,075,575
Cost of Sales	(759,960)	(788,530)	(394,440)	(413,480)	(3,094,517)	(2,880,148)	(1,768,561)	(1,889,251)
<b>Gross Profit</b>	<b>1,390,841</b>	1,239,523	<b>778,932</b>	759,793	<b>4,810,693</b>	4,960,653	<b>2,601,317</b>	3,186,324
Other Operating Income	60,556	(18,192)	15,773	12,893	111,131	25,570	51,737	39,984
Administrative Expenses	(837,966)	(696,070)	(535,703)	(482,502)	(2,873,353)	(2,853,962)	(1,803,783)	(2,016,681)
Other Operating Expenses	(367,779)	(238,122)	(158,009)	(152,573)	(1,102,987)	(770,783)	(523,774)	(489,777)
<b>Results from Operating Activities</b>	<b>245,652</b>	287,139	<b>100,993</b>	137,611	<b>945,484</b>	1,361,478	<b>325,497</b>	719,850
Finance Cost	(33,056)	(21,006)	(22,308)	(14,728)	(87,898)	(80,566)	(61,999)	(70,786)
Finance Income	4,146	26,435	(25,772)	4,717	207,062	81,822	294,804	253,213
Gain on Bargain Purchase	-	(1,235)	-	-	-	14,453	-	-
Share of Profit of an Equity Accounted Investee	-	2,147	-	-	-	11,724	-	-
<b>Profit before Taxation</b>	<b>216,742</b>	293,480	<b>52,913</b>	127,599	<b>1,064,648</b>	1,388,910	<b>558,302</b>	902,276
Taxation	(152,173)	(67,293)	(142,895)	(37,602)	(418,757)	(279,384)	(263,620)	(131,726)
<b>Net Profit after Taxation</b>	<b>64,569</b>	226,187	<b>(89,982)</b>	89,997	<b>645,891</b>	1,109,526	<b>294,682</b>	770,550
<b>Other Comprehensive Income</b>								
<b>Items will not be reclassified to profit or loss</b>								
Net Change in Fair Value on Equity Investments at FVTOCI	7,041	(4,991)	(646)	(2,168)	12,198	(2,351)	5,712	472
Actuarial Gain/(Loss) on Gratuity Valuation	(17,931)	56,265	(15,640)	54,510	(17,931)	56,265	(15,640)	54,510
Deferred Tax Charge on Actuarial Gain/(Loss) on Gratuity Valuation	5,379	(5,440)	4,692	(7,631)	5,379	(6,010)	4,692	(7,631)
Deferred Tax (charge)/Reversal on Revaluation Surplus	(127,828)	3,743	(115,721)	3,743	(411,399)	-	(399,292)	-
Other Comprehensive Income for the period	(133,339)	49,577	(127,315)	48,453	(411,753)	47,904	(404,528)	47,351
<b>Total Comprehensive Income for the period</b>	<b>(68,770)</b>	275,764	<b>(217,297)</b>	138,451	<b>234,138</b>	1,157,430	<b>(109,846)</b>	817,901
Profit Attributable to:								
Equity Holders of the Parent	45,058	193,729	(89,982)	89,997	566,073	982,324	294,682	770,550
Non-Controlling Interest	19,511	32,459	-	-	79,818	127,202	-	-
	<b>64,569</b>	226,187	<b>(89,982)</b>	89,997	<b>645,891</b>	1,109,526	<b>294,682</b>	770,550
Total Comprehensive Income Attributable to:								
Equity Holders of the Parent	(87,190)	243,098	(217,297)	138,451	155,638	1,029,378	(109,846)	817,901
Non-Controlling Interest	18,420	32,666	-	-	78,501	128,052	-	-
	<b>(68,770)</b>	275,764	<b>(217,297)</b>	138,451	<b>234,138</b>	1,157,430	<b>(109,846)</b>	817,901
<b>Earnings per Share - Basic</b>	<b>1.33</b>	5.72	<b>(2.66)</b>	2.66	<b>16.71</b>	29.00	<b>8.70</b>	22.75

The above figures are provisional and subject to audit.

## Consolidated Statement of Financial Position

	GROUP		COMPANY	
	Unaudited As at 31/03/2023 Rs. '000	Audited As at 31/03/2022 Rs. '000	Unaudited As at 31/03/2023 Rs. '000	Audited As at 31/03/2022 Rs. '000
<b>ASSETS</b>				
<b>Non-Current Assets</b>				
Property, Plant and Equipment	10,310,463	8,481,203	7,232,844	5,592,128
Right of Use Assets	261,135	288,954	261,135	288,954
Investments in Subsidiary	-	-	1,457,821	1,457,821
Other Financial Assets	286,005	272,923	79,181	71,416
Prepaid Rent	-	890	-	-
	<b>10,857,603</b>	<b>9,043,970</b>	<b>9,030,981</b>	<b>7,410,319</b>
<b>Current Assets</b>				
Inventories	1,020,132	835,149	807,593	693,571
Trade and Other Receivables	276,466	306,454	154,145	214,955
Advances & Prepayments	726,559	252,441	378,560	195,053
Amount Due from Related Parties	5,329	1,934	42,725	75,921
Other Financial Assets	789,484	1,451,388	40,686	659,287
Tax Refund Due	13,607	13,278	13,262	13,259
Cash and Cash Equivalents	425,545	898,189	275,221	129,295
	<b>3,257,122</b>	<b>3,758,833</b>	<b>1,712,192</b>	<b>1,981,341</b>
<b>Total Assets</b>	<b>14,114,725</b>	<b>12,802,803</b>	<b>10,743,173</b>	<b>9,391,660</b>
<b>EQUITY AND LIABILITIES</b>				
<b>Equity Attributable to Equity holders of the parent</b>				
Stated Capital	1,142,798	916,366	1,142,798	916,366
Revaluation Reserve	2,282,544	2,691,662	1,735,252	2,134,544
Fair Value Reserve	76,843	65,868	6,312	600
Revenue Reserves	4,256,310	3,873,950	2,807,750	2,695,436
	<b>7,758,495</b>	<b>7,547,846</b>	<b>5,692,112</b>	<b>5,746,946</b>
Non-Controlling Interests	729,425	734,254	-	-
<b>Total Equity</b>	<b>8,487,920</b>	<b>8,282,100</b>	<b>5,692,112</b>	<b>5,746,946</b>
<b>Non-Current Liabilities</b>				
Interest Bearing Loans and Borrowings	2,135,972	1,701,501	2,000,782	1,606,247
Deferred Revenue	-	-	30,470	31,470
Retirement Benefit Obligations	205,414	177,998	182,727	156,790
Deferred Tax Liabilities	1,325,892	707,793	1,023,951	452,599
	<b>3,667,278</b>	<b>2,587,292</b>	<b>3,237,930</b>	<b>2,247,106</b>
<b>Current Liabilities</b>				
Bank Overdraft	483,403	246,765	387,320	94,527
Interest Bearing Loans and Borrowings	520,602	306,060	435,538	248,830
Trade and Other Payables	881,712	1,247,893	436,695	862,449
Taxation Payable	73,810	127,894	31,670	73,281
Amount Due to Related Parties	-	4,799	521,908	118,521
	<b>1,959,527</b>	<b>1,933,411</b>	<b>1,813,131</b>	<b>1,397,608</b>
<b>Total Equity and Liabilities</b>	<b>14,114,725</b>	<b>12,802,803</b>	<b>10,743,173</b>	<b>9,391,660</b>

The above figures are provisional and subject to audit.

Sgd  
**Thusitha Rubasinghe**  
 Chief Financial Officer

The Board of Directors is responsible for the preparation and presentation of these Financial Statements.  
 Signed for and on behalf of the Board by,

Sgd  
**A E Tudawe**  
 Chairman

Sgd  
**U D Tudawe**  
 Director

31st May 2023

**CEYLON HOSPITALS PLC**  
**Consolidated Statement of Changes in Equity**

Group	Attributable to equity holders of the parent					Non-Controlling Interests	Total Equity
	Stated Capital Rs. '000	Revaluation Reserve Rs. '000	Fair Value Reserve Rs. '000	Revenue Reserves Rs. '000	Total Rs. '000		
<b>Balance as at 31st March 2021</b>	916,366	2,691,662	68,436	2,951,439	6,627,903	592,626	7,220,529
Net Profit for the Year	-	-	-	982,324	982,324	127,202	1,109,526
<b>Other Comprehensive Income</b>							
Actuarial Gain on Gratuity Valuation	-	-	-	55,965	55,965	300	56,265
Deferred Tax effect on Gratuity Valuation	-	-	-	(6,342)	(6,342)	332	(6,010)
Prior Year Adjustments - Inventory Written-off	-	-	-	(989)	(989)	(230)	(1,219)
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	(2,568)	-	(2,568)	217	(2,351)
Share Buyback	-	-	-	(54)	(54)	-	(54)
<b>Total Comprehensive Income for the Year</b>	-	-	(2,568)	1,030,904	1,028,335	127,822	1,156,158
<b>Transactions with Owners in their capacity as Owners</b>							
Non-Controlling Interest on Acquisition of Subsidiary	-	-	-	-	-	127,301	127,301
Dividend Paid - Ordinary Shares	-	-	-	(108,393)	(108,393)	(113,495)	(221,888)
	-	-	-	(108,393)	(108,393)	13,806	(94,587)
<b>Balance as at 31st March 2022</b>	916,366	2,691,662	65,868	3,873,950	7,547,846	734,254	8,282,100
Net Profit for the year ended 31 March 2023	-	-	-	566,073	566,073	79,818	645,891
<b>Other Comprehensive Income</b>							
Net Gain/ (Loss) on Gratuity Valuation	-	-	-	(17,562)	(17,562)	(369)	(17,931)
Deferred Tax Effect on Gratuity Valuation	-	-	-	5,269	5,269	110	5,379
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	10,976	-	10,976	1,222	12,198
Deferred Tax Effect on Revaluation Surplus	-	(409,118)	-	-	(409,118)	(2,281)	(411,399)
<b>Total Comprehensive Income for the year ended 31 March 2023</b>	-	(409,118)	10,976	553,780	155,638	78,500	234,138
<b>Transactions with Owners in their capacity as Owners</b>							
Shares issued at Rights Issue by subsidiary	-	-	-	-	-	5,860	5,860
Shares issued at Rights Issue	226,432	-	-	-	226,432	-	226,432
Rights Issue Expenses	-	-	-	(2,056)	(2,056)	-	(2,056)
Dividend Paid - Ordinary Shares	-	-	-	(169,364)	(169,364)	(89,190)	(258,554)
	226,432	-	-	(171,420)	55,012	(83,330)	(28,318)
<b>Balance as at 31st March 2023</b>	1,142,798	2,282,544	76,843	4,256,310	7,758,495	729,425	8,487,920
<b>Company</b>							
	Stated Capital Rs. '000	Revaluation Reserve Rs. '000	Fair Value Reserve Rs. '000	Revenue Reserves Rs. '000	Total Rs. '000		
<b>Balance as at 31st March 2021</b>	916,366	2,134,544	128	1,986,400	5,037,438		
Net Profit for the Year	-	-	-	770,550	770,550		
<b>Other Comprehensive Income</b>							
Actuarial Gain on Gratuity Valuation	-	-	-	54,510	54,510		
Deferred Tax Effect on Gratuity Valuation	-	-	-	(7,631)	(7,631)		
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	472	-	472		
<b>Total Comprehensive Income for the Year</b>	-	-	472	817,429	817,901		
<b>Transactions with Owners in their capacity as Owners</b>							
Dividend Paid - Ordinary Shares	-	-	-	(108,393)	(108,393)		
	-	-	-	(108,393)	(108,393)		
<b>Balance as at 31st March 2022</b>	916,366	2,134,544	600	2,695,436	5,746,946		
Net Profit for the year ended 31 March 2023	-	-	-	294,682	294,682		
<b>Other Comprehensive Income</b>							
Actuarial Loss on Gratuity Valuation	-	-	-	(15,640)	(15,640)		
Deferred Tax Effect on Actuarial Loss	-	-	-	4,692	4,692		
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	5,712	-	5,712		
Deferred Tax Effect on Revaluation Surplus	-	(399,292)	-	-	(399,292)		
<b>Total Comprehensive Income for the year ended 31 March 2023</b>	-	(399,292)	5,712	283,734	(109,846)		
<b>Transactions with Owners in their capacity as Owners</b>							
Shares issued at Rights Issue	226,432	-	-	-	226,432		
Rights Issue Expenses	-	-	-	(2,056)	(2,056)		
Dividend Paid - Ordinary Shares	-	-	-	(169,364)	(169,364)		
	226,432	-	-	(171,420)	55,012		
<b>Balance as at 31st March 2023</b>	1,142,798	1,735,252	6,312	2,807,751	5,692,112		

## Consolidated Statement of Cash Flows

	Group		Company	
	Unaudited Year Ended 31/03/2023 Rs '000	Audited Year Ended 31/03/2022 Rs '000	Unaudited Year Ended 31/03/2023 Rs '000	Audited Year Ended 31/03/2022 Rs '000
<b>Cash Flows from/ (Used in) Operating Activities</b>				
Net Profit Before Income Tax Expenses	1,064,648	1,388,911	558,302	902,276
Adjustments for :				
Inventory Write-off/(Write in)	7,018	25,388	3,920	21,790
Bad Debts Write-off	68,789	19,490	(7,416)	12,010
Depreciation Charge for the year	389,264	339,848	212,151	185,027
Amortisation of Right to use assets	112,768	108,031	116,248	108,031
Finance Income	(207,062)	(81,822)	(294,804)	(253,213)
Finance Cost	87,898	80,567	61,999	70,786
Amortisation of Deferred Rent Expenses/(Income)	-	100	(5,371)	(1,790)
(Profit)/ Loss on Disposal of Property, Plant and Equipment	-	(5,202)	-	(5,202)
Fair value (Gain)/Loss on Financial Instruments	(29,970)	(32,917)	(3,546)	472
Reversal of provisions	(24,816)	-	-	-
Impairment on Receivables	2,171	-	-	-
Share of Profit of an Equity Accounted Investee	-	(11,724)	-	-
Provision for Defined Benefit Plans	41,212	28,948	36,052	25,089
Operating Profit before Working Capital Changes	1,511,920	1,859,618	677,535	1,065,276
(Increase)/Decrease in Inventories	(192,001)	(324,660)	(117,942)	(264,887)
(Increase)/Decrease in Trade and Other Receivables	(511,182)	(184,978)	(115,281)	(143,615)
Increase/(Decrease) in Trade and Other Payables	(338,191)	576,763	(425,754)	477,733
(Increase)/Decrease Related Party Dues	(8,194)	(171,712)	436,581	(51,357)
Cash Generated from Operations	462,352	1,755,031	455,139	1,083,150
Finance Cost Paid	(87,898)	(51,361)	(61,999)	(41,581)
Defined Benefit Plan Costs Paid	(30,753)	(37,567)	(25,754)	(30,868)
Income Tax Paid	(247,569)	(160,869)	(117,482)	(109,439)
Net Cash from Operating Activities	96,132	1,505,234	249,904	901,262
<b>Cash Flows from/ (used in) Investing Activities</b>				
Acquisition of Property, Plant and Equipment	(2,218,525)	(1,109,961)	(1,852,867)	(697,335)
Proceeds from Sale of Property, Plant and Equipment	-	8,750	-	8,750
(Acquisition)/ Disposal of other Investments	680,414	(422,851)	620,095	(540,616)
Income from Investments	207,062	81,822	294,804	253,213
Net Cash Flows from/ (used in) Investing Activities	(1,331,049)	(1,442,240)	(937,968)	(975,988)
<b>Cash Flows from/ (used in) Financing Activities</b>				
Receipts from Interest Bearing Loans and Borrowings	875,000	1,019,154	750,000	900,909
Re-payments to Interest Bearing Loans and Borrowing	(206,771)	(740,022)	(149,540)	(699,802)
Lease Rent Payment	(114,275)	(135,537)	(114,275)	(135,537)
Share buy back	-	(54)	-	-
Non-Controlling Interest on Acquisition of Subsidiary	-	248,399	-	-
Proceeds on Shares issued at Rights Issue	226,432	-	226,432	-
Changes in Non-controlling interest on issue of shares by subsidiary	5,860	-	-	-
Right Issue Expenses	(2,056)	-	(2,056)	-
Dividends Paid	(258,554)	(221,888)	(169,364)	(108,393)
Net Cash Flows from/ (used in) Financing Activities	525,636	170,052	541,197	(42,823)
<b>Net Increase/ (Decrease) in Cash and Cash Equivalents</b>	(709,281)	233,045	(146,867)	(117,549)
<b>Cash and Cash Equivalents at the Beginning of the Year</b>	651,423	418,379	34,768	152,317
<b>Cash and Cash Equivalents at the End of the Year</b>	(57,858)	651,424	(112,099)	34,768
<b>Analysis of Cash and Cash Equivalents</b>				
Bank Overdraft	(483,403)	(246,765)	(387,320)	(94,527)
Cash in Hand and at Bank	425,545	898,189	275,221	129,295
	(57,858)	651,424	(112,099)	34,768

**Explanatory Notes****01. CORPORATE INFORMATION**

Ceylon Hospitals PLC is a public limited company incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. Ordinary shares of the company are listed on the Colombo Stock Exchange.

**02. INTERIM CONDENSED FINANCIAL STATEMENTS**

The financial statements for the year ended 31 March 2023, includes "the Company" referring to Ceylon Hospitals PLC, as the holding company and "the Group" referring to the companies whose accounts have been consolidated therein.

**03. APPROVAL OF FINANCIAL STATEMENTS**

The interim condensed financial statements of the Group and the Company for the year ended 31 March 2023 were authorised for issue by the Board of Directors on 31st May 2023.

**04. BASIS OF PREPARATION AND CHANGES TO ACCOUNTING POLICIES****4.1 Basis of preparation**

The interim financial statements for the year ended 31 March 2023 have been prepared in accordance with LKAS 34 Interim Financial Reporting.

The interim condensed financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 March 2022.

**4.2 Fair value measurement and related fair value disclosures**

The fair values of all the financial assets and financial liabilities recognised during the quarter were not materially different from the transaction prices at the date of initial recognition. There were no transfers between Level 1 and Level 2 and no transfers into or out of Level 3 categories as per the fair value hierarchy, during the quarter. The fair value changes on financial instruments in Level 3 category was properly recorded in the statement of other comprehensive income and there were no purchases and/or disposals during the period.

Fair valuation was done as of 31 March 2023 for all unquoted equity shares classified as Level 3 within the fair value hierarchy according to fair valuation methodology. Fair value would not significantly vary if one or more of the inputs were changed.

**05. Capital Commitments**

The Project 2022 undertaken in FY 2018/19 is now nearing completion and the total construction cost is expected to be Rs. 2.51 Bn excluding VAT. The Main Constructor for the Project 2022 is M/s Tudawe Brothers ( Pvt ) Ltd that is a Related Party to the Company.

06. There were no contingent liabilities as at the Balance Sheet date which would require adjustment or disclosure in the Financial Statements.

**07. Events occurring after the Balance Sheet date**

The Company declared an interim Dividend of Rs.2.30 per share for the financial year 2022/23.

08. Related party transactions for the quarter ended 31 March 2023 were reviewed by the Related Party Transactions Review Committee and it was decided there were no transactions requiring Board Approval, immediate CSE disclosure or Shareholder approval.

## Related Party Transactions

For the year ended 31 March 2023 - In Rs. '000

For the year ended 31 March 2023 - in Rs. 000				
Name of the Related Party	Relationship	Transactions	Nature	Aggregate Value of Related Party Transactions
Durdans Management Services Ltd	Ultimate Parent	Management fee	Recurrent	42,937
		Providing utilities and other cost	Recurrent	1,017
		<b>Total</b>		<b>43,954</b>
Durdans Medical and Surgical Hospital (Pvt) Ltd	Subsidiary	Sales of Drugs and consumables	Recurrent	37,268
		Rendering of medical services	Recurrent	512,958
		Sharing of utilities and other cost	Recurrent	625,728
		Purchases of Drugs and consumables	Recurrent	37,186
		Receiving of medical services	Recurrent	218,100
		Receiving of utilities and other cost	Recurrent	100,163
	<b>Total</b>		<b>1,531,403</b>	
Durdans Heart Centre (Pvt) Ltd	Subsidiary	Sales of Drugs and consumables	Recurrent	5,095
		Rendering of medical services	Recurrent	118,005
		Sharing of utilities and other cost	Recurrent	133,722
		Purchases of Drugs and consumables	Recurrent	13,651
		Receiving of medical services	Recurrent	54,989
		Sharing of utilities and other cost	Recurrent	1,385
	<b>Total</b>		<b>326,847</b>	
Amrak Institute of Medical Sciences (Pvt) Ltd	Subsidiary	Rendering of utilities and other cost	Recurrent	16,568
		<b>Total</b>		<b>16,568</b>
Ceygen Biotech (Pvt) Ltd	Subsidiary	Providing utilities and other cost	Recurrent	2,499
		<b>Total</b>		<b>2,499</b>
Commercial Marketing Distributors (Pvt) Ltd	Affiliate	Sale of Drugs and consumables	Recurrent	2,012
		Purchases of Drugs and consumables	Recurrent	204,666
		<b>Total</b>		<b>206,678</b>
Tudawe Brothers (Pvt) Ltd	Affiliate	Rendering of medical services	Recurrent	87
		<b>Total</b>		<b>87</b>

Name of the Related Party	Relationship	Transactions	Nature	Aggregate Value of Related Party Transactions
Tudawe Brothers (Pvt) Ltd	Affiliate	Project 2022 Construction Cost	Non Recurrent	542,006
		<b>Total</b>		<b>542,006</b>
Tudawe Engineering Services (Pvt) Ltd	Affiliate	Project 2022 Construction Cost	Non Recurrent	50,735
		<b>Total</b>		<b>50,735</b>

**Share Information**
**Number of Shares Represented in Stated Capital**

Voting Shares	27,122,726
Non-Voting Shares	8,867,044
Total	<b>35,989,770</b>

**Public Shareholding as at 31st March 2023**

	<b>Voting</b>	<b>Non-Voting</b>
Number of shareholders	2,365	1,338
Number of shares	5,944,080	4,541,592
Holding Percentage	21.92%	51.22%
Float Adjusted Market Capitalisation (Rs Mn)	804	
Float Adjusted Market Capitalisation Option	Less than 2.5 Bn (Option 5)	

**Directors' and Chief Executive Officer's Shareholding as at 31st March 2023**

	<b>Number of Shares</b>	
	<b>Voting</b>	<b>Non-Voting</b>
Mr. A. E. Tudawe	235,152	-
Mr. U. D. Tudawe	181,279	-
Dr A. D. P. A. Wijegoonewardene	234,368	-
Mr. Y. N. R. Piyasena	532,312	-
Mr. A. S. Abeyewardene	1,530	1,275
Mr. A. D. B. Talwatte	1,062	-
Mr. A.V.R. De Silva Jayatilleke	106	-
Mr. A.S. Tudawe	51	1,062

**Market Prices recorded during the Quarter**

	<b>Highest Traded Price</b>		<b>Lowest Traded Price</b>		<b>Last Traded Price</b>	
	<b>2022/23</b>	<b>2021/22</b>	<b>2022/23</b>	<b>2021/22</b>	<b>2022/23</b>	<b>2021/22</b>
	<b>Rs.</b>	<b>Rs.</b>	<b>Rs.</b>	<b>Rs.</b>	<b>Rs.</b>	<b>Rs.</b>
Voting	<b>151.50</b>	235.00	<b>125.50</b>	101.50	<b>132.25</b>	104.50
	<b>19/01/2023</b>	02/02/2022	<b>24/01/2023</b>	30/03/2022	<b>31/03/2023</b>	31/03/2022
Non - Voting	<b>122.75</b>	160.00	<b>85.00</b>	80.50	<b>95.40</b>	82.20
	<b>14/02/2023</b>	02/02/2022	<b>24/03/2023</b>	30/03/2022	<b>30/03/2023</b>	30/03/2022

**Per Share Ratios**

	<b>Group</b>		<b>Company</b>	
	<b>As at</b>	<b>As at</b>	<b>As at</b>	<b>As at</b>
	<b>31/03/2023</b>	<b>31/03/2022</b>	<b>31/03/2023</b>	<b>31/03/2022</b>
	<b>Rs.</b>	<b>Rs.</b>	<b>Rs.</b>	<b>Rs.</b>
Earnings Per Share	<b>16.71</b>	28.06	8.70	22.06
Net Asset Per Share	<b>229.01</b>	222.03	<b>168.01</b>	169.08



**Top 20 Shareholders Listed as at 31 March 2023**

**Voting Shareholders**

<b>Name of the Shareholder</b>	<b>Country of Residence</b>	<b>Number of Shares</b>	<b>Holding %</b>
Durdans Management Services Ltd	Sri Lanka	18,628,342	68.68
Lawrance Tudawe Management Services (Pvt) Ltd	do	637,581	2.35
Mr. Y. N. R. Piyasena	do	532,312	1.96
Mr. Deen Mohamed Fazal Aslam	do	504,206	1.86
Galle Face Capital Partners PLC	do	447,774	1.65
Mr. Merrill J. Fernando	do	390,500	1.44
Cargo Boat Development Company PLC	do	324,577	1.20
Mr. D.G. Wijemanna	do	322,328	1.19
MJF Holdings Ltd	do	287,917	1.06
Mr.R.P. Weerasooriya	do	261,484	0.96
Mr. A. E. Tudawe	do	235,152	0.87
Dr. A. D. P. A. Wijegoonewardene	do	234,368	0.86
Miss. T. T. Weerasinghe	do	206,250	0.76
Mrs. H. K. Weerasinghe	do	203,000	0.75
Mrs. L. I. Weerasinghe	do	201,000	0.74
Mr. U. D. Tudawe	do	181,279	0.67
Mr. H. L. Tudawe	do	175,433	0.65
Mr. A. D. Tudawe	do	172,108	0.63
Mr. P. V. Tudawe	do	166,789	0.61
Mr. A. H. Munasinghe	do	96,624	0.36
		<b>24,209,024</b>	<b>89.26</b>

**Non-Voting Shareholders**

<b>Name of the Shareholder</b>	<b>Country of Residence</b>	<b>Number of Shares</b>	<b>Holding %</b>
Durdans Management Services Ltd	Sri Lanka	2,912,948	32.85
Employees' Provident Fund	do	1,154,371	13.02
MJF Holdings Ltd	do	636,061	7.17
E W Balasuriya & Co. (Pvt) Ltd	do	351,282	3.96
Mr. A. H. Munasinghe	do	170,663	1.92
Mr. D. Ratnayake	do	156,045	1.76
Tudawe Engineering Services (Pvt) Ltd	do	97,735	1.10
Mr. D. A. Cabraal	do	87,656	0.99
Mr. S. S. Sithambaranathan	do	82,612	0.93
Mr. A. D. Tudawe	do	75,597	0.85
Mr. P. S. De Mel	do	75,248	0.85
Ms. T. T. Weerasinghe	do	70,485	0.79
Commercial Bank of Ceylon PLC A/C No. 04	do	64,918	0.73
Peoples Leasing & Finance PLC /Mr. P. A. I. S. Perera	do	63,750	0.72
Mr. D.P. L. De Mel	do	62,589	0.71
Saman Villas Limited	do	62,115	0.70
Mr.D.G. Wijemanna	do	53,264	0.60
Mr. H. A. Cabraal	do	53,125	0.60
Mr. G. D. M. Ranasinghe	do	53,125	0.60
Mr. U. D. Wickremesooriya	do	53,125	0.60
		<b>6,336,714</b>	<b>71.46</b>

# CEYLON HOSPITALS PLC

## CORPORATE INFORMATION

### **Name of Company**

Ceylon Hospitals PLC

### **Brand Name**

DURDANS

### **Legal Form**

A quoted public company with limited liability incorporated in Sri Lanka under the Companies Ordinance No.51 of 1938 and registered under the Companies Act No.07 of 2007.

### **Company Registration Number**

PQ 113

### **Stocks Exchange Listing**

The Ordinary Shares of the Company are listed on the Colombo Stock Exchange of Sri Lanka.

### **Registered Office**

No.03, Alfred Place, Colombo 03.

### **Bankers**

Bank of Ceylon  
Commercial Bank of Ceylon PLC  
DFCC Bank PLC  
Hatton National Bank PLC  
National Development Bank PLC  
Nations Trust Bank PLC  
Sampath Bank PLC  
Seylan Bank PLC  
Union Bank of Colombo PLC  
People's Bank

### **Auditors**

Messers.B.R.De.Silva & Co.  
Chartered Accountants  
No. 22/4,Vijaya Kumaratunga Mawatha  
Colombo 05.

### **Lawyers**

Mr. D.F.R. Jayamaha  
Hector Jayamaha Law Office,  
No.228,Thimbirigasyaya Road,  
Colombo 05.

### **Secretaries**

Nexia Corporate Consultants (Pvt) Ltd  
No. 130, Level 02, Nawala Road,  
Narahenpita. Colombo 05.

### **Registrars**

S S P Corporate Services (Pvt) Ltd  
546, Galle Road,  
Colombo 03.